In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

May maybes as Spanish in prepares to pay back d€bt €Billions to pharma

This article was originally published in Scrip

Executive Summary

There is soon to be some relief for pharmaceutical companies in Spain that have been struggling to recover hospital debts related to drug purchases totalling €6.3 billion. A €35 billion "liquidity injection" from the central Spanish government should see regional and local authorities start to pay back providers, said the treasury this week. However, it is far from clear that the financial jab in the arm provides any comfort for the pharma industry beyond the immediate future.

You may also be interested in...



What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Profile: Meindert Boysen On What Companies Should Expect From NICE And The Benefits Of Hill Walking

In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Topics

UsernamePublicRestriction

Register

SC016547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel